

SUSTAINABILITY IN BIOPHARMACEUTICAL INDUSTRY

J. Muthukumar¹, Niraj Kumar Jha²

^{1,2}Dept. of Biotechnology, Sharda University, Greater Noida, Uttar Pradesh

Email Id- ¹j.muthukumar@sharda.ac.in, ²niraj.jha@sharda.ac.in

Received: 02 November 2019 Revised and Accepted: 02 January 2020

ABSTRACT: The production of biopharmaceuticals is also an essential aspect of modern medical system, which provides guidance to severe and chronic diseases for rapidly evolving treatments composed of highly complicated biomolecules. Although this sector keeps growing, it has a strong "wham-to-bust" productivity which threatens its long-period viability. Potential manufacturing developments indicate a shift to continuous flow processes 'self-use techniques that present problems for conservation, but work in this area is minimal and fails to recognize diverse social, and financial relationships. There are many different definitions of sustainability; however, it generally refers to utilizing the absolute minimum of the non-renewable resources and not damaging the earth. The pharmaceutical industry is one of the world's largest and most important sectors. For everything from cancer, cystic fibrosis and Parkinson's disease to traditional antibiotics and pain relief medications, it is responsible for studying, developing, manufacturing and subsequently marketing pharmaceutical vaccines, drugs, and therapies. This paper outline a vision based on sustainability and propose research opportunities to help create a more integrated approach that would improve the industry's sustainability.

KEYWORDS: Biopharmaceuticals, Biomolecules, Chronic disease, Pharmaceutical industry, Sustainability.

I. INTRODUCTION

Biopharmaceuticals are essential and altering parts of the contemporary health care system but are pharmaceutical companies obtained from natural sources. The very first biopharmaceutical therapy in the late nineteenth century may be known to have originated with the creation of the first vaccinations and the rise of healthy, regular blood transfusions. [1] Then drugs like insulin through animal foods and antibiotics were found and introduced in the beginning of the 2.0th century, whose manufacturing scale was established during World War 2. In 19.73, Cohen and Boyer invented DNA as a template as a sea change; the implications of this development were in 19.82, with both the FDA approval of humanized monoclonal insulin produced through E genetic engineering. [2] The decades following it, a range of failing, paralytic viruses have been developed with significant effects on increased lifespans, and replication with DNA technology has increased. The Food & Drug Administration (FDA) scientifically authorized the very first genetic examination for idiopathic impairment. [3] Promotion of regenerative medicine is another paradigm change in biopharmaceutical advancement, promising innovative medications for a variety of disorders, including mucopolysaccharidosis and hemophilia offering a single dose of therapeutic benefit (favorable treatment response) compared to the prolonged use needed for the contemporary treatments.

1. Technological considerations for the manufacturing of biopharmaceuticals:

1.1. Biopharmaceutical Medicine structure:

In comparison with biologically synthesized samples with understandable structures though with a molar size not frequently greater than about a kilo dalton (kDa) biopharmaceuticals, the amount of molar size in the orders is often more complex than that of proteins. Such molecular dimension and complexity means that biopharmaceuticals-based drugs need additional considerations, including immunogenic (causing inflammatory reactions in the body) as opposed to chemically synthesized products. [4] Crumpling and modification molecules and metaph resistance, heat, enzyme breakdown, as well as other process parameters. Proteins like insulin, a hormone which regulates person's body function, and somatotropin, or the estrogen, are the easiest

biopharmaceuticals that facilitate person's body adopt effective, growth, and production. These (fairly) basic proteins are biochemical in the patient's psyche after biosynthesis pathway in the cell membrane after RNA is transferred to ribosome without any further chemical method. [5] The hot cell's post - transcriptional modifications specifications during muscle growth in the ribosome of a host organism were due to the growing specificity of biopharmaceutical enzymes. Upon transformations of RNA messengers into the ribosomes, the adjustment is related to protein synthesis, mostly by enzyme-based reagggregations, and is used as a glycosylation for the development of the original peptide bond and is found in several bio-pharmaceutical protectors. [6] So the glycosylated antigen has a low immune response, increase in durability and able to priorities in the body, glycosylation has a beneficial impact on protein folding and stabilization and is essential part of the development process [7] Its most complicated biopharmaceutical items are those produced by hbv infection, with a special mention of gene therapy virulence factors. Therapies like these use very complex particles, like viral capsides, which have a molecular weight approaching 1 MDa in the adeno-connected capsid virus. [8] The mode of action in gene therapy differs from existing treatments for biopharmaceuticals. Most biopharmaceuticals are also meant to substitute or augment drugs which are not normally formed in the body, mostly because of a defective or lacking chromosome. In order to have continuing medicinal benefit, [9] the continued administration of these types of substances treated is necessary. In case of regenerative medicine, the faulty or missing gene is replaced by a well functioned gene which helps the body to generate the previous missing product for a longer period and theoretically indefinitely. This fully functioning genes is primarily implemented through the use of virulence factors, viruses that are designed to suppress possible pathogenic behaviour, and also to convert the genetic code into individual body cells. This is a dynamic procedure which requires the addition of genes to different cells to ensure that the desired product is preserved.

1.2. Current state of the biopharmaceuticals manufacturing process

Contemporary development of biopharmaceutical drugs takes place through the use of big ships of metal where a culture media digests the development medium, either an antigen or a viral in the case of particular vaccines or new treatments, for the purpose of generating the required content. This element is then extracted in several stages of purifying from the supernatant cell: centrifugation, filtering range, tangential filtration, homogenization and chromatography to obtain high pureness and aim identification rates for the drug. [10] Many biopharmaceuticals are parenterally administered. Many possibilities for the development of biopharmaceutical drugs are available in the cancer cell. Cells also contain bacterial crops such as E. Coli, the stem cells kidneys (HEK 293), the mosquito cultures and crop cultures, mammalian cultivations, such as child hamster kidneys (BHK), Chinese hamster ovaries (CHO). The tissue culture choice is decided and influenced by the amount of material produced throughout process growth. For example, the mammalian cell cultures produce mostly glycoproteins, as mammal atoms that form post - transcriptional changes similar to some of those created by humans.

Within bacterial or yeast cell cultures like *S. cerevisiae* or *E. coli*, proteins that May not necessitate substantial post-translational modifications could be created [3]. Mammalian society is most popular in the growth of the infectious therapeutic gene treatment. Adenovirus and adeno-associated virus production in HEK 29.3 cultured cells has been thoroughly recorded, since HEK 293 cell culture exemplifies some proteins essential to transmit adenoviruses and adeno-associated viral. [11] Cell is fermented naturally by either feeding batch or oxygenation. Fermentation is finished. The Fed-batch cellular culture is comprised of scale-up steps in many the size bioreactors, before the cell cultivation in the bioreactor array has achieved a maximal cell density of more than 40,000 L of length.

2. Future trends in biopharmaceutical manufacture

2.1 One-use technology

One-use production is an alternative to the conventional stainless steel processing techniques. Dual uses equipment made up predominantly of plastics provides the possibility of modular, multi-product applications in which a major regulatory issue is eliminated. [9] Material distribution risks are minimized. Additional gain in the form of lower return on capital and debuting power in facility sharing is a fascinating proposition for one-use technologies. [12] Individual product concerns also include health threat from leached and retrievable potential for clinicians, volumetric restriction of roughly 20.00 l and the overall supply chain threat due to the low number of vendors. utilization of perfusion cultured cells in bioreactors for solitary-use applications is scarce in research over a longer duration of 2.8 days, although the business needs up to 20.0 days. [13] Extensive perfusion project operation increases the risk of pollution due to higher interaction with operators and the opportunity to increase leakage and insolubility because of long-term exposure with high-temperature cellular cultivation of the

bioreactor bottle. The use of sole use schemes, in the light of growing volumes of organic waste which are required for disposal, poses major economical and operational concerns. [2] Most of it is comprised of products that cannot be easily recycled and are recycled for waste or decomposition at the conclusion of the lifespan, which raise sustainability issues.

a) Continuous downstream processing

Although continuous downward operations in the context of perfusion cultured cells are widely recognized in the field of biopharmaceutical development. Whereas the new model for large fed-batch cultured cells that feed equally large batch cleaning trains has resulted in the need for improved volumetric productivity with the above-mentioned cost savings, decreased capital spending and the decrease in total cost of products.

Although single-use technology partly solves this, it does not affect the volumetric efficiency problem by reducing the footprint of the facility and capital expenditure. As a result, it becomes desirable to implement continuous manufacturing. In combination with It could be done utilizing perfusion cell culture, through continuous operations with purifiers like tangential fluid disinfection and chromatography. It is easy to deliver constantly cleaning using the new equipment. There are major obstacles to its practical application, from technological problems to the creation of a robust incubation device for action like viral removal and diafiltration. to uncertainties concerning the economic benefits anticipated to be achieved on a commercial scale and, perhaps most importantly, regulatory requirements to adjust product registrations. The production and adoption of the persistent purification data processing will remain hampered by existing industries until market research is conducted and evaluated.

b) Drug discovery and optimization

Gene therapy is highly thrilling from a modern viewpoint of drug development and the first of which gained FDA clearance globally following initial 1992 gene therapy. The clinical effect and bio-similar development face problems for current medicines. The majority of licensed medications are currently expected to manufacture high doses of therapy ($> 1 \text{ mg / kg}$), which contributes to annual grammatical patients. Glycosylation type, complexity and concentration, contributing to the need for elevated-dosage distribution, affect the strength and efficacy of these medicines. [12] The solution to this issue is to increase awareness of the mechanisms used in current production processes or to find and approve biosimilar that are more treatment effective. Those demands are going to push companies to manufacture existing products or to deal with reduced cost and/or increased medicinal rewards from bio-similar. In conclusion, the development of biopharmaceutical production is based on low volume, high-power therapies in portable, multiple-product plants using consistent processing and solitary-use technologies as illustrated in Fig.1.




Figure 1: Overall trend in biopharmaceutical research and innovation

3. Considerations of environmental growth and biopharmaceutical work

3.1. Sustainability perspectives for the pharmaceutical sector

Sustainable development has been suggested as a concept to encourage the ability to survive on this earth for a long time, i.e. over several years to come. An integrated viewpoint is a central feature of sustainable theory, that of understanding the function and impact of distinct (but essentially interconnected) components in the development of a greater dynamic structure. [14] The standard economic threat/ benefit evaluation is a traditionally specific decision dimension, under the predominant market-based societal paradigm which shapes our surroundings (whose question of where and whom the profit and costs are assigned as a topic of conflict). Thus the economic and social effects of environmental factors are often omitted or marginal in comparison to others on the shareholders' financial "end result.". Once the studies on environmental change speed were made, a strong focus was placed on the impact of "business as normal" financial policies; the tremendous decline in diversity and the emergence of challenges to global supply of freshwater. Therefore, several businesses are now reviewing their processes carefully to mitigate environmental harm from the operations as these existential threats are being gradually recognized.

4. Next moves in biopharmaceutical sustainable development

Although work conducted in the area presents findings on the ecological impact in a number of forms of biopharmaceutical processing, restricted study provides knowledge on preferred production methods from a holistic perspective integrating the three main facets of sustainability thinking: society, culture and atmosphere. In contrast, biopharmaceutical material planning has been guided almost exclusively around the industry by cost / benefit analyses and will not even consider larger environmental considerations such as irrigation or asset use. From a public viewpoint, the consequences of the biopharmaceutical manufacturing lifespan still have not been generally reported but instead debated on the grounds of the component meal by utilizations of process-level processes, including life-cycle costs for economic efficiency and the tier of the consumer. [6] Consequently, it is evident that an integrated sustainability assessment of the results of biopharmaceutical development is required in an essential and system-wide manner.

The study of resources and energy movements by industrial processes is known as business biology and is considered to be the relationship between ecosystem, an ecosystem in which all livelihood depends for its existence, and technology a technical advancement in which mankind relies for the transfer of raw resources from an ecosystem to useful products and services. Link simulation can be achieved with the preceding using an urban ecology microscope:

- Class 1 Prototypical- Model directly integrating the environmental, technical or humanoid aspects (E.g. process modeling, economic evaluations, and ecological impression valuations).
- Class 2 Prototypical- Model combining two environmental, technical or humanoid factors (e.g. lifespan evaluation, eco-design and life cycle costing).
- Class 3 Prototypical - Model integrating integrated environmental, technical and humanoid aspects in

comprehensive style.

II. CONCLUSION

Biopharmaceutical drugs tend to gain significant popularity, offering substantial societal benefits in the management of pain illnesses and malaises. Humanity confronts larger threats in terms of the degradation of habitats, global climate change and growing economic disparities. The sustainable industry should apply the concepts to consider the potential effect on culture, economies and the climate of the production of biopharmaceuticals and to contribute substantially to the future welfare of humans. Trends in the biopharmaceutical industry demonstrate that manufacturing processes are fully continuous with a solitary-use system to manufacture several high-power therapies in lightweight processing facilities. The treatment plants of using cultured cells in combination with single-use technologies are shown in proven research; furthermore, there is insufficient evidence available that provides politicians and judgement makers with inadequate advice on environmentally sustainable processing paths. The viability of existing practices must be evaluated and the interconnected viewpoints must be established.

III. REFERENCES

- [1] W. Lazonick and Ö. Tulum, "US biopharmaceutical finance and the sustainability of the biotech business model," *Res. Policy*, 2011.
- [2] F. Lalor, J. Fitzpatrick, C. Sage, and E. Byrne, "Sustainability in the biopharmaceutical industry: Seeking a holistic perspective," *Biotechnology Advances*. 2019.
- [3] M. S. Kinch and R. Moore, "Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry," *Cell Chemical Biology*. 2016.
- [4] M. J. Ahn and M. Meeks, "Building a conducive environment for life science-based entrepreneurship and industry clusters," *J. Commer. Biotechnol.*, 2008.
- [5] X. M. Fu, S. S. Jiang, N. Wang, S. Q. Wang, and C. Y. Wang, "The Research on international development path of China's marine biopharmaceutical industry," *Sustain.*, 2018.
- [6] C. Song and K. Shin, "Business model design for latecomers in biopharmaceutical industry: The case of Korean firms," *Sustain.*, 2019.
- [7] D. J. Pollard and A. Pralong, "Single-Use Technology Implementation for Biologics and Vaccines Production," in *Biopharmaceutical Processing: Development, Design, and Implementation of Manufacturing Processes*, 2018.
- [8] J. Zeng, D. Liu, and H. Yi, "Agglomeration, structural embeddedness, and enterprises' innovation performance: An empirical study of Wuhan biopharmaceutical industrial cluster network," *Sustain.*, 2019.
- [9] S. Casper and H. Kettler, "The Road to Sustainability in the UK and German Biotechnology Industries," *Monographs*, 2000.
- [10] K. T. Jurieva, "Methodical bases of identification and ranking of developed cluster groups of regional economy (case study: St. Petersburg)," in *Proceedings of the 25th International Business Information Management Association Conference - Innovation Vision 2020: From Regional Development Sustainability to Global Economic Growth, IBIMA 2015*, 2015.
- [11] A. Bansal, "As You Sow, so Shall You Reap: Evidence of Innovation and Drug Portfolio Diversification from the Stock Market," *SSRN Electron. J.*, 2012.
- [12] R. Cabela, "What management strategies can a pharmaceutical company implement to sustain innovation?," *Muma Bus. Rev.*, 2018.
- [13] A. L. Sánchez Regla, A. L. Ortiz Guzmán, M. del P. M. Pérez Hernández, I. Rivera, and S. M. Pérez Tapia, "Mecanismos de transferencia de tecnología como elementos del fortalecimiento del conocimiento acumulado en la industria biofarmacéutica mexicana: El Caso de la UDIBI – IPN," *Nov. Sci.*, 2019.
- [14] W. Lazonick and O. Tulum, "US Biopharmaceutical Finance and the Sustainability of the Biotech Business Model," *SSRN Electron. J.*, 2013.